All In Biotech

Drug Trial Radar · NCT07617363

ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

A Phase I Study of ATRN-119, an ATR Inhibitor, in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Oct 31, 2029

Study completion Nov 30, 2031

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aprea Therapeutics; National Cancer Institute (NCI); The V Foundation for Cancer Research
First posted
Jun 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This single-center, open-label, phase I study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antileukemic activity of ATRN-119 (mosipasertib) alone and in combination with decitabine in patients with TP53-mutated AML or higher-risk myelodysplastic syndrome (HR-MDS). The primary objective is to identify the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE) of ATRN-119 (mosipasertib) plus decitabine. The study is based on the hypothesis that ATR inhibition with ATRN-119 (mosipasertib) will enhance sensitivity to decitabine in TP53-mutated disease, resulting in deeper and more durable clinical responses.

Conditions

  • Acute Myeloid Leukemia
  • High-risk Myelodysplastic Syndrome

Interventions

  • ATRN-119Drug

    Provided in 50 mg and 100 mg capsules or 50 mg and 250 mg tablets and are administered by mouth.

  • DecitabineDrug

    Decitabine is provided as a 50 mg injection in a single-dose vial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and grade of treatment-emergent adverse events (TEAEs) as assessed via CTCAE v6.0 (All Patients)Time frame: From start of treatment until 30 days after last dose of ATRN-119 (approximately 23 months)
  2. Incidence of dose-limiting toxicities (DLTs) during Cycle 1 as assessed via CTCAE v6.0 (All Patients)Time frame: From Cycle 1 Day 1 to end of Cycle 1 Day 28/Cycle 1 Day 42 (total time 28-42 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.